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First-Generation
Drug-Eluting Stents
for Chronic Total Occlusion
In Danger of Extinction?*
Joachim Schofer, MD
Hamburg, Germany
An attempt to recanalize a chronic total occlusion (CTO) is
only made in one-half of the patients presenting with an
occluded vessel during angiography (1). Possible reasons for
hesitating to perform a percutaneous coronary intervention
(PCI) for a CTO may be the length and complexity of the
procedure and the accordingly lower procedural success rate
(2). Hence, patients with CTO are, in case of single-vessel
disease, often managed medically or, in case of multivessel
disease, are likely scheduled for bypass graft surgery even if
the remaining lesions are suitable for PCI. In 2 randomized
trials comparing coronary artery bypass surgery with PCI,
CTO remains the strongest predictor of referral to bypass
surgery rather than randomization (3,4).
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The presumably most important development, which
stimulated the interest in CTO-PCI, was the advent of
drug-eluting stents (DES). With bare-metal stents, any
effort by the interventionalist and burden for the patient
associated with a recanalization procedure was cursed with a
restenosis rate of 30% to 50% and a reocclusion rate of up to
20% (5). In contrast, the introduction of DES directly
correlated with dramatically improved restenosis and reoc-
clusion rates (6,7).
With this newfound potential to keep a recanalized
coronary artery open, enormous efforts have been made
recently to improve the success rate of the procedure, which
remained stable at 50% to 70% for over 25 years (8).
Technological advances and procedural developments in-
clude retrograde wiring through collateral channels, both
antegrade and retrograde subintimal dissection, and re-entry
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to disclose.techniques. Data from trials conducted in the United States
(9), Europe (10), and Japan (11) show that in specialized
centers with high operator volume, procedure success rates
of 80% to 90% are now achievable.
In this issue of the Journal, Valenti et al. (12) assessed the
incidence of reocclusion and predictors of angiographic
failure after successful DES-supported recanalization of
CTO from a single-center registry comprising 1,035 pa-
tients. Sixty-six percent of the successfully recanalized
patients received a paclitaxel- or sirolimus-eluting stent
(first-generation DES), 34% an everolimus-eluting stent
([EES]; second-generation DES). Follow-up angiography
was performed 6 to 9 months after successful intervention in
82% of eligible patients. The main findings of the study are
a significantly lower reocclusion rate of 3% for the EES
compared with 10.1% for the other DES and a reocclusion
rate of 57% after successful subintimal tracking and re-entry
technique. In a multivariate analysis, the subintimal tracking
and re-entry technique was highly associated with reocclu-
sion (odds ratio [OR]: 29.5). Although performed in only a
small subset of patients (4%), this confirms the very high
reocclusion rate found by others (13). As the investigators
suggested, its application should be limited to a small subset
of patients with no other therapeutic options.
What characterizes this study is the difference in the
performance of second- versus first-generation DES in
CTO. Multivariate analysis revealed the use of EES (OR:
0.22) as an independent predictor of risk of reocclusion.
These findings were substantiated by a propensity score–
matched analysis.
Newer DES have a stent platform of a cobalt-chromium
alloy and are thinner than the first-generation DES and are
less likely to cause vessel trauma. Later-generation stents
also have improved biocompatibility, resulting in less of an
inflammatory response and more rapid vessel endotheliali-
zation or healing. For nonocclusive lesions, it has been
shown that second-generation DES perform better than
first-generation DES do (14,15). By contrast, for CTO,
data on this issue are scarce (16,17). The investigators are to
be commended for providing us with new information on
the performance of EES in CTO in a fairly high number of
patients with angiographic follow-up.
Does the present study put the whammy on the first-
generation DES in CTO? This may be too early to conclude
for several reasons. First, although this is the largest series of
angiographic follow-ups after CTO-PCI to date, the data
are derived from a single-center nonrandomized registry.
Among CTO patients comorbidities and lesion morpholo-
gies are very variable and for the complex procedures
different techniques are applied. These confounding factors
cannot be excluded other than by performing an additional,
randomized trial. Second, the EES findings cannot neces-
sarily be applied to other second-generation DES. Third,
the differences were only seen in the reocclusion rate and not
in the binary restenosis rate. Unfortunately, the investigators
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the reasons for reocclusion. Was this a result of diffuse
intima proliferation or rather a late thrombotic event? In
many patients with reocclusion of a CTO, these events are
not accompanied by symptoms. If thrombosis is the main
mechanism, antiplatelet agents more potent than clopi-
dogrel could potentially diminish the differences seen in the
reocclusion rate between both groups of stents (18,19),
which might still keep first-generation DES on the shelf.
In conclusion, first-generation DES for CTO will stay
alive until randomized trials have clearly demonstrated their
inferiority in terms of safety and efficacy compared with that
of newer generation DES, but they are in danger of
extinction.
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